Your browser doesn't support javascript.
loading
Phase Ia/b Study of Giredestrant ± Palbociclib and ± Luteinizing Hormone-Releasing Hormone Agonists in Estrogen Receptor-Positive, HER2-Negative, Locally Advanced/Metastatic Breast Cancer.
Jhaveri, Komal L; Bellet, Meritxell; Turner, Nicholas C; Loi, Sherene; Bardia, Aditya; Boni, Valentina; Sohn, Joohyuk; Neilan, Tomas G; Villanueva-Vázquez, Rafael; Kabos, Peter; García-Estévez, Laura; López-Miranda, Elena; Pérez-Fidalgo, J Alejandro; Pérez-García, Jose M; Yu, Jiajie; Fredrickson, Jill; Moore, Heather M; Chang, Ching-Wei; Bond, John W; Eng-Wong, Jennifer; Gates, Mary R; Lim, Elgene.
  • Jhaveri KL; Department of Medicine, Breast Medicine Service, Memorial Sloan Kettering Cancer Center, New York, New York, and Weill Cornell Medical College, New York, New York.
  • Bellet M; Oncology Department, Breast Cancer Unit, Vall d'Hebron University Hospital and Vall d'Hebron Institute of Oncology, Barcelona, Spain.
  • Turner NC; Royal Marsden Hospital and Institute of Cancer Research, London, United Kingdom.
  • Loi S; Division of Cancer Research, Peter MacCallum Cancer Centre, Melbourne, and The Sir Peter MacCallum Department of Medical Oncology, The University of Melbourne, Parkville, Australia.
  • Bardia A; Department of Medicine, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts.
  • Boni V; START Madrid-CIOCC, Centro Integral Oncológico Clara Campal, HM Hospitales Sanchinarro, Madrid, Spain.
  • Sohn J; Division of Medical Oncology, Department of Internal Medicine, Yonsei Cancer Center, Yonsei University College of Medicine, Seoul, Republic of Korea.
  • Neilan TG; Division of Cardiology, Department of Medicine, Cardio-Oncology Program, Massachusetts General Hospital, Boston, Massachusetts.
  • Villanueva-Vázquez R; Institut Català d'Oncologia, l'Hospitalet-Hospital Duran i Reynals, Barcelona, Spain.
  • Kabos P; School of Medicine, University of Colorado, Aurora, Colorado.
  • García-Estévez L; Breast Cancer Department, MD Anderson Cancer Center Madrid, Madrid, Spain.
  • López-Miranda E; Medical Oncology Department, Hospital Universitario Ramón y Cajal, Madrid, Spain.
  • Pérez-Fidalgo JA; Hospital Clínico Universitario de Valencia, INCLIVA, CIBERONC, Valencia, Spain.
  • Pérez-García JM; International Breast Cancer Center (IBCC), Pangaea Oncology, Quiron Group, Barcelona, Spain.
  • Yu J; Medica Scientia Innovation Research (MEDSIR), Barcelona, Spain and Ridgewood, New Jersey.
  • Fredrickson J; Clinical Pharmacology, Genentech, Inc., South San Francisco, California.
  • Moore HM; Genentech Research and Early Development (gRED), Genentech, Inc., South San Francisco, California.
  • Chang CW; Oncology Biomarker Development, Genentech, Inc., South San Francisco, California.
  • Bond JW; PHC and Early Development Oncology Biostatistics, Genentech, Inc., South San Francisco, California.
  • Eng-Wong J; Product Development Safety, Genentech, Inc., South San Francisco, California.
  • Gates MR; Genentech Research and Early Development (gRED), Genentech, Inc., South San Francisco, California.
  • Lim E; Genentech Research and Early Development (gRED), Genentech, Inc., South San Francisco, California.
Clin Cancer Res ; 30(4): 754-766, 2024 02 16.
Article en En | MEDLINE | ID: mdl-37921755
Asunto(s)
Texto completo
Imprimir
XML
PubMed Links
Search on Google

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Piperazinas / Piridinas / Neoplasias de la Mama / Carbolinas Límite: Female / Humans Idioma: En Año: 2024 Tipo del documento: Article
Texto completo
Imprimir
XML
PubMed Links
Search on Google

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Piperazinas / Piridinas / Neoplasias de la Mama / Carbolinas Límite: Female / Humans Idioma: En Año: 2024 Tipo del documento: Article